Jakarta, 29 April 2025, Based on the Consolidated Financial Statements of PT Enseval Putera Megatrading Tbk and its Subsidiaries ("the Company") dated 31 March 2025 and for the period ended on that date (Unaudited), the Company hereby informs that in the first quarter of 2025, the Company's Net Sales were recorded at Rp8,307.89 billion, growing by 4.15 % compared to Net Sales in the first quarter of 2024 which were recorded at Rp7,976.52 billion. 

The Company's Cost of Goods Sold in the first quarter of 2025 was recorded at Rp7,433.93 billion, increasing by 4.17 percent compared to the first quarter of 2024 which was recorded at Rp7,136.51 billion.

Thus, the Company recorded a Gross Profit of Rp873.96 billion in the first quarter of 2025, growing by 4.04 percent compared to the Gross Profit in the first quarter of 2024 which was recorded at Rp840.01 billion.

In the first quarter of 2025, the Company's Operating Expenses were recorded at Rp515.08 billion, consisting of Selling Expenses of Rp457.24 billion and General and Administrative Expenses of Rp57.83 billion, or an increase of 4.46 percent compared to the first quarter of 2024. Consequently, the Company recorded an Operating Profit of Rp358.89 billion, increasing by 3.45 percent compared to the Operating Profit in the first quarter of 2024 which was recorded at Rp346.92 billion.

The Company's Profit Before Income Tax in the first quarter of 2025 was recorded at Rp357.54 billion, increasing by 0.91 percent compared to the same period in 2024. The composition of Other Income (Expenses) consisted of Financial Income of Rp3.62 billion, Financial Expenses of Rp5.10 billion, Final Tax Expenses of Rp0.87 billion, Share of Net Profit from Associates of Rp1.86 billion, Other Operating Income of Rp7.78 billion, and Other Operating Expenses recorded at Rp8.64 billion.

The Company's Income Tax Expense in the first quarter of 2025 was recorded at Rp77.12 billion, increasing by 1.18 percent compared to the same period in 2024 which was recorded at Rp76.21 billion.

Thus, the Company recorded a Net Profit for the Period of Rp280.42 billion in the first quarter of 2025, increasing by 0.84 percent compared to the same period in 2024 which was recorded at Rp278.09 billion.

From the comparison of the Company's Consolidated Financial Position as of 31 March 2025 (Unaudited) with the Consolidated Financial Position as of 31 December 2024 (Audited), the Company's Total Assets increased by 10.21 percent, from Rp11.49 trillion to Rp12.66 trillion. The Company's Total Liabilities increased by 22.82 percent from Rp3.91 trillion as of 31 December 2024 to Rp4.80 trillion in the first quarter of 2025. Consequently, the Company's Total Equity increased by 3.70 percent from Rp7.58 trillion to Rp7.86 trillion in the first quarter of 2025.

Performance of Each Division

Currently, the Company has 7 Divisions, consisting of the Consumer Goods Division, Prescription Drugs Division, Over-the-Counter Drugs Division, Raw Materials for Sale Division, Medical Equipment Division, Veterinary and Livestock Drugs Division, and Healthcare and Transportation Services Division.

The details of each Division's performance within the Company can be described as follows:

• Consumer Goods Division, the division with the largest contribution to total Net Sales at 37.46 percent. In the first quarter of 2025, this division recorded Net Sales of Rp3,111.84 billion, slightly decreasing by 3.00 percent compared to the same period in 2024.

• Prescription Drugs Division, contributing the second largest after the Consumer Goods Division with a contribution of 33.99 percent. As of the first quarter of 2025, the Prescription Drugs Division recorded Net Sales of Rp2,823.65 billion, growing by 9.52 percent compared to the same period in 2024.

• Over-the-Counter Drugs Division recorded Net Sales of Rp1,295.36 billion in the first quarter of 2025 with a contribution of 15.59 percent, increasing by 7.19 percent compared to the same period in 2024.

• Raw Materials Division recorded Net Sales of Rp611.20 billion in the first quarter of 2025, increasing by 9.65 percent compared to the same period in 2024, with a contribution of 7.36 percent.

• Medical Equipment Division contributed 5.19 percent in the first quarter of 2025, with Net Sales recorded at Rp431.04 billion, increasing by 9.08 percent compared to the same period in 2024.

• Net Sales from the Veterinary and Livestock Drugs Division were recorded at Rp14.73 billion, increasing by 5.52 percent compared to the same period in 2024 which was recorded at Rp13.96 billion. This division contributed 0.18 percent to the Company's total Net Sales.

• Net Sales from the Healthcare and Transportation Services Division were recorded at Rp20.08 billion, increasing by 32.44 percent compared to the same period in 2024. This division contributed 0.24 percent.